Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05091060 |
Recruitment Status :
Terminated
(Sponsor decision)
First Posted : October 25, 2021
Results First Posted : August 1, 2023
Last Update Posted : August 30, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tinnitus | Device: Erchonia HLS | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 5 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Erchonia and InnerScope, Pilot Evaluation of the Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms |
Actual Study Start Date : | June 10, 2021 |
Actual Primary Completion Date : | March 14, 2022 |
Actual Study Completion Date : | March 14, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Erchonia HLS
635 nanometers (nm) laser application
|
Device: Erchonia HLS
56 procedure administrations with the Erchonia® HLS™ administered by the subject at home: daily procedure administrations for 8 weeks. |
- Total Score on the Tinnitus Handicap Inventory (THI). [ Time Frame: Baseline and 8 week ]The Tinnitus Handicap Inventory (THI) is a 25-item questionnaire to assess how tinnitus affects an individual's life. Each question is responded to as 'yes' (4 points); 'sometimes' (2 points) or 'no' (0 points). The individual scores for the 25 questions are added to get a total THI score from 0 to 100. The higher the total THI score, the greater the negative impact tinnitus has on the individual's life. Change in total THI score is calculated as total THI score after the eight week procedure administration phase minus total THI score at baseline. A positive (+) change in total THI score indicates the negative impact of tinnitus on the individual's everyday life has worsened. A negative (-) change indicates the negative impact of tinnitus on the individual's everyday life has improved (lessened).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjective tinnitus
- Tonal tinnitus.
- Constant tinnitus on-going at least half the time over at least the past 6 months.
- Willing to abstain from other tinnitus-related treatments except prior hearing aid use throughout the study duration.
- Willing and able to refrain from activities or work involving excessive noise exposure without the use of effective hearing protection throughout study participation.
- 18 years of age or older
- Primary language is English
Exclusion Criteria:
- Objective tinnitus
- Atonal, pulsatile, intermittent, or occasional tinnitus
- Severe or profound hearing loss in one or both ears
- Current or prior surgically removed acoustic neuroma
- Consistent use of any of the following drugs known to cause or increase tinnitus (primarily ototoxins) within the past 30 days:
NSAIDS (motrin, naproxen, relafen, etc) aspirin (exceeding 300mg per day) and other salicylates Lasix and other "loop" diuretics "mycin" antibiotics such as vancomycin quinine and related drugs Chemotherapy agents such as cis-platin
- Acute or chronic vertigo/dizziness
- Ménière's disease
- Prior stapendectomy
- Prior mastoidectomy
- Auditory nerve tumor (acoustic neuroma), current or surgically removed in the past
- Active infection/wound/external trauma to the areas to be treated with the laser
- Medical, physical or other contraindications for, or sensitivity to, light therapy
- Pregnant, breast feeding, or planning pregnancy prior to the end of study participation
- Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05091060
United States, California | |
Kathy Amos | |
Walnut Creek, California, United States, 94598 |
Documents provided by Erchonia Corporation:
Responsible Party: | Erchonia Corporation |
ClinicalTrials.gov Identifier: | NCT05091060 |
Other Study ID Numbers: |
R-Tinnitus-Pilot |
First Posted: | October 25, 2021 Key Record Dates |
Results First Posted: | August 1, 2023 |
Last Update Posted: | August 30, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Tinnitus Hearing Disorders Ear Diseases Otorhinolaryngologic Diseases |
Sensation Disorders Neurologic Manifestations Nervous System Diseases |